Related Experiment Videos

Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer

C N Sternberg¹, M K Parmar

¹Vincenzo Pansadoro Foundation, Rome, Italy. cstern@mclink.it

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

|September 19, 2001

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy.

Urologic oncology·2025

Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.

ESMO open·2023

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.

ESMO open·2022

Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.

ESMO open·2021

See all related articles